This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

MACE (major adverse cardiac events)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • term MACE, defined as 'major adverse cardiac events,' is arguably the most commonly used composite end point in cardiovascular research
    • term MACE appears to have originated in the mid-1990s with its use restricted primarily to in-hospital complications related to percutaneous coronary interventions

  • there is no standard definition of MACE, it is routinely used and reported for procedural, short-term, and long-term outcome evaluations, and may involve other cardiovascular treatments (2)

  • a review (2) suggested that 'Varying definitions of composite end points, such as MACE, can lead to substantially different results and conclusions. Therefore, the term MACE, in particular, should not be used, and when composite study end points are desired, researchers should focus separately on safety and effectiveness outcomes, and construct separate composite end points to match these different clinical goals...'

Reference:

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.